Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Bestet al. describe a diagnostic platform based on platelet RNA sequencing and self-learning algorithms that discriminates patients with cancer from healthy controls, predicts the localization of the primary tumour and provides information on the molecular tumour phenotype.
Three studies demonstrate that adenosine-to-inosine RNA editing introduces transcriptome diversity in tumours from a range of cancer types and show that this diversity is both functionally important and clinically relevant.
Roger Lo and colleagues characterized the melanoma genome, transcriptome and epigenome to understand the landscape of acquired resistance to MAPK pathway inhibitors.
A study published inCancer Cellreports that two FDA-approved drugs — an antidepressant and an anticoagulant — synergize to promote autophagy and slow glioma progression in mice.
Chi Dang and colleagues show that MYC is involved in the regulation of the circadian clock, and its deregulated expression in cancer cells leads to a loss of cellular circadian rhythm and impacts cell metabolism.
Three papers have reported new data on resistance to bromodomain and extraterminal (BET) inhibitors and how best to use these inhibitors in combination therapy.
Two studies published inCellhave shown that reduction of glucose levels in the tumour microenvironment by highly glycolytic tumour cells reduces the ability of tumour-infiltrating lymphocytes to trigger an antitumour immune response.
Westbrook and colleagues show that knockdown of spliceosome components causes synthetic lethality in cells with hyperactive MYC, highlighting a possible therapeutic opportunity.
